Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Update

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 242,900 shares, a growth of 6.9% from the February 29th total of 227,200 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average trading volume of 75,100 shares, the days-to-cover ratio is currently 3.2 days.

Eton Pharmaceuticals Trading Down 2.2 %

ETON opened at $3.60 on Thursday. The firm has a market capitalization of $92.48 million, a PE ratio of -120.00 and a beta of 1.17. Eton Pharmaceuticals has a twelve month low of $2.42 and a twelve month high of $5.81. The firm’s 50-day moving average price is $4.27 and its 200 day moving average price is $4.20.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). The business had revenue of $7.31 million for the quarter, compared to analyst estimates of $7.70 million. Eton Pharmaceuticals had a negative return on equity of 6.21% and a negative net margin of 2.96%. As a group, analysts predict that Eton Pharmaceuticals will post 0.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at about $46,000. Virtu Financial LLC acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at about $57,000. Renaissance Technologies LLC acquired a new position in Eton Pharmaceuticals in the 1st quarter valued at about $52,000. Jane Street Group LLC acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at about $43,000. Finally, Goldman Sachs Group Inc. acquired a new position in Eton Pharmaceuticals in the 1st quarter valued at about $77,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Eton Pharmaceuticals in a research report on Monday, December 11th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.